Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Míreanna comhchosúla

• Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
  de réir: Dalle, S, et al.
  Foilsithe / Cruthaithe: (2019)
• Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis
  de réir: Sasson, SC, et al.
  Foilsithe / Cruthaithe: (2019)
• Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis
  de réir: Sasson, SC, et al.
  Foilsithe / Cruthaithe: (2019)
• Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
  de réir: Dalle, S, et al.
  Foilsithe / Cruthaithe: (2021)
• A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio
  de réir: Mulholland, PJ, et al.
  Foilsithe / Cruthaithe: (2023)